




Innovative Medicines Initiative: Tipps für EinreicherInnen und Services der FFG

Dr. Ylva Huber
Europäische und Internationale Programme

1. Juli 2011, Wien



- Tipps für einen erfolgreichen Antrag:
Grundsätzliche Überlegungen
Wichtige Dokumente
Kommentare aus Evaluierungsreports
- Services der FFG



Einreichen bei IMI? Wichtige Gesichtspunkte



Programm mit sehr hoher internationaler Aufmerksamkeit

Längerfristige Projekte mit gut dotiertem Budget

Aussicht auf langfristige Kooperationen mit Pharmaindustrie:
Verwertungschancen; Vernetzung

Kompetitives Programm

Detailliert definierte Themen

Fokus auf „Tool-Entwicklung“:
z.B. Assays, Tiermodelle, Biomarker

Förderung indirekter Kosten zu 20 % oder „real indirect costs“

IMI „IP Policy“ unterscheidet sich von jener des 7. RP -> Verhandlungsspielräume wichtig

Wichtige Dokumente



IMI Call Topics

Guide for Applicants

IMI Rules for Participation

IMI Model Grant Agreement

IMI Strategic Research Agenda

Rules for submission

Evaluation forms

IMI IP Policy, + Clarification Note



www.imi.europa.eu

http://rp7.ffg.at/health_jti_imi_dokumente

Evaluierung: Die Kriterien

Stufe 1 (1)



Evaluation Form – Stage 1	
<p>1. Scientific and/or technological excellence</p> <p>1.1. Quality and soundness of the scientific and/or technological approach</p> <p>1.2. Likelihood of the research proposal to meet all the key objectives in order to complement the EFPIA Consortium.</p> <p>1.3. Innovation (i.e. novelty in discovery, practical applicability, adaptation, etc), progress beyond the state-of-the-art.</p> <p>1.4. Degree of scientific and/or technological impact likely to be delivered?</p> <p>1.5. In relation to 1.4, has the Applicant Consortium adequately explained the balance between potential impact and residual risks based on the proposed approach i.e. are potential complications, alternative strategies, and benchmarks for success presented?</p> <p><i>Evaluators - Please insert comments here:</i></p>	<p>.</p> <p>Score: .../5</p> <p><i>Weight: 5</i></p> <p>Weighted score: .../25</p> <p><i>Threshold: 19/25</i></p>
<p>2. Excellence of Partnership</p> <p>2.1. Scientific quality and technological expertise of the individual participants in the Applicant Consortium.</p> <p>2.2. Ability to provide the contributions expected from the Applicant Consortium.</p> <p>2.3. Unique features, strengths, internal complementarities and balance of the Applicant Consortium (including appropriate allocation of roles, manageability of consortium and input of each participant).</p> <p><i>Evaluators - Please insert comments here:</i></p>	<p>.</p> <p>Score: .../5</p> <p><i>Weight: 3</i></p> <p>Weighted score: .../15</p> <p><i>Threshold: 10/15</i></p>



Evaluierung: Die Kriterien

Stufe 1 (2)



<p>3. Work-plan outline</p> <p>Conceptual quality and soundness of the work-plan outline, including approximate budget, timelines for deliverables.</p> <p><i>Evaluators - Please insert comments here:</i></p>	<p>Score: .../5</p> <p><i>No weight</i></p> <p><i>No threshold</i></p>
--	---



Evaluierung: Die Kriterien

Stufe 2(1)



<p>1. Scientific and/or technological excellence</p> <ul style="list-style-type: none">• <i>Soundness and quality of approach to meet the objectives of the call topic</i>• <i>Application of creative and cutting edge methodologies</i>• <i>Uniqueness of the approach (no duplication of existing initiative)</i>• <i>Where applicable, any ethical issues appropriately addressed.</i> <hr/> <p><i>[Evaluators comments to be inserted here.]</i></p>	<p>Score: .../5</p> <p>(Threshold 3.00/5.00)</p>
---	--

Evaluierung: Die Kriterien Stufe 2(2)



<p>2. Excellence of the project implementation plan</p> <ul style="list-style-type: none">• <i>Adequate and appropriate representation of all relevant stakeholders within the consortium.</i>• <i>Adequate documentation of the project plan with efficient timelines and well utilised resources. Includes justification of timelines and resource allocation (e.g. for research, management, training or other activities).</i>• <i>Resource allocation (by value) by the EFPIA project participants should at least equal the funding requested by the participants eligible for funding by the IMI JU (if not, the unequal resource allocation is adequately justified).</i>• <i>Adequate documentation and appropriateness of the management structure and procedures. Management plan capable of building a cohesive and efficient team within the consortium.</i> <hr/> <p><i>[Evaluators comments to be inserted here.]</i></p>	<p>Score: .../5</p>
--	----------------------------

Evaluierung: Die Kriterien Stufe 2(3)



<p>3. Consistency with Call Topic and stage 1</p> <ul style="list-style-type: none">• <i>Scope of Full Project Proposal is consistent with the Call Topic published in November 2009.</i>• <i>Full Project Proposal contains core objectives and plans that do not substantially deviate in scope from the Expression of Interest selected at Stage 1, except to fulfil recommendations from the Stage 1 peer review.</i>• <i>The composition of the applicant consortium does not substantially deviate from that described in the Expression of Interest selected at Stage 1, except where adequately justified or to fulfil recommendations from the Stage 1 peer review.</i> <p>-----</p> <p><i>[Evaluators comments to be inserted here.]</i></p>	<p>Score:/5</p>
<p>4. Potential impact of project results</p> <p><i>Likelihood of IMI key benefits (i.e. new multidisciplinary development tools, new development paradigms) to be achieved following dissemination / publication of research results.</i></p> <p>-----</p> <p><i>[Evaluators comments to be inserted here.]</i></p>	<p>Score:/5</p>




Beispielkommentare aus Evaluierungsreports



Science + Technological Excellence



- integrative and mechanistic approach to all objectives
- good balance between innovation and application
- highly likely to achieve major breakthroughs
- unique integrated approach,...highly appropriate models



Science + Technological Excellence

- objectives poorly addressed
- approach lacks focus and cohesion
- too narrow in scope for the IMI call
- how will preclinical and clinical work be bridged
- animal model for "condition X" is not ideal
- "X Vaccines" are not the focus of the EFPIA Partners..
- not clear how preclinical activities will translate to a more effective drug discovery effort
- concern: proposal relies exclusively on "X" technology; competing proposals cover broader range of models as stated in the goals
- insufficiently defined models/parameters
- need for innovation not sufficiently addressed
- activities for identification and validation of biomarkers are not clearly separated
- neglect to mention work that contradicts applicant's hypothesis, no quotation of competing work
- study lacks power to draw statistically reliable conclusions
- no description of quality assurance mechanisms



Excellence of partnership



- reasonable number of partners with long experience and excellent reputations
- acknowledged experts, leaders in their field
- applicant consortium leader very well qualified
- complementary and manageable contributions
- balanced consortium, good internal complementarity

Excellence of partnership




- ...difficult to understand how the consortium would leverage competencies in the EFPIA partners to achieve the objectives of the project
- Expertise in the area of X must be incorporated
- specific input of each partner should be better described
- lack of SME partners
- consider participation of patient organisations
- not clear which partners contribute to which work packages
- some partners seem not effectively integrated with the rest of the consortium and their role is marginal

Work Plan Outline




- measured and balanced approach...impressive workplan
- work plan outline is sound and with high conceptual quality
- key outputs summarised
- analytical approaches and endpoints clearly described
- reasonable timelines for deliverables



Work Plan Outline



- overall strategy and workplan is cursory
- budget not proportionally distributed - only weak correlation to deliverables
- Work Package X did not fit well with the other work packages



Erfolgsfaktoren



- Alle „**indicative expectations** from the Applicant Consortium“ abgedeckt
- **Innovation**, neue Zugänge
- Alle benötigten, **komplementären Top-Expertisen** im Konsortium;
- „unique features“; (innovative KMUs; regulatorische Behörden, PatientInnenverbände, etc), klare Rollen für alle Partner
- Komplementarität/geplante **Kooperation** mit **EFPIA**-Partnern gut durchdacht -> Recherche: Publikationen der EFPIA-Partner
- Realistischer, gut strukturierter , „integrativer“ **Arbeitsplan**;
- „risks and contingencies“ dargestellt
- Gute „Brücken“ zwischen **Prälinik, Klinik, „Drug discovery“**
- Effiziente **Management**-Struktur; evtl. Advisory Board
- Veranschlagtes **Budget** gut begründet
- Berücksichtigung der „**IMI IP Policy**“

Partnersuche für IMI-Projekte



The image shows a screenshot of the IMI Participant Search interface. At the top left is the IMI logo and the text 'Innovative Medicines Initiative'. Below it is a navigation menu with 'Home', 'My Data', 'Participant Search', and 'Log Out'. The main content area is titled 'Participant Search' and includes a search criteria section with a list of checkboxes for various expertise areas such as 'Pre-clinical expertise', 'Clinical expertise', 'Systems modelling', 'Statistical analysis', 'Systems Biology models', 'Mathematical modelling in vivo models', 'In vitro models cultured hepatocyte', 'Non-parenchymal cells', 'Multiple preclinical data types integration', 'Toxicity identification', 'Risk assessment models', 'Cell culture', 'Evaluation of evidence-based scientific data', 'Experimental design', 'Stem cells', 'Immune response or immune-mediated response', and 'Genetic susceptibility'. The interface also features sections for 'LATEST NEWS' and 'UPCOMING EVENTS'.

The image shows a screenshot of the IMI Partnering Platform interface. At the top, it features the 'Federal Ministry of Education and Research' logo and the 'INNOVATIVE MEDICINES INITIATIVE' banner. A navigation menu on the left includes 'Home', 'Call 2009', 'Partner search', 'Events', 'Links', 'Contact', 'Register and Privacy', and 'Register Users'. The main content area is titled 'Welcome to the IMI Partnering Platform' and contains several sections: 'Registration', 'Call 2009', 'Partner Search', 'Matchmaking & Alerts', and 'My profile'. A 'News / Upcoming Events' sidebar on the right lists '1st Call 2009' and '2nd IMI Call 2009'. The interface is designed with a clean, professional layout using green and white colors.

<http://www.imi.europa.eu/content/partner-search>

www.imi-partnering.eu

Information und Beratung



- IMI-Website der FFG: http://rp7.ffg.at/health_jti_imi
- Newsletter
- Unterstützung bei Partnersuchen
- Projektstart EU-Förderung für KMUs
- **Proposal Checks:** Expressions of Interest/ Full Proposals
- Beratung zu IPR-Fragen
- Feedback/Input an IMI JU im Rahmen der States Representatives Group (SRG)

A screenshot of the FFG website's 'Europäisches Forschungsrahmenprogramm' section. The page is titled 'Innovative Medicines Initiative (IMI)'. It features a navigation menu on the left with categories like 'Gesundheit', 'Lebensmittel, Landwirtschaft und Fischerei, und Biotechnologie', 'Informatik- und Kommunikationstechnologien', 'Nanowissenschaften, Nanotechnologien, Werkstoffe und neue Produktionstechnologien', 'Energie', 'Umwelt (einschließlich Klimawandel)', 'Verkehr (einschließlich Luftfahrt)', 'Sozial-, Wirtschafts- und Gesellschaftswissenschaften', 'Medizin', and 'Sicherheit'. The main content area includes a 'Kurzbeschreibung' of the IMI, stating its goal to reduce barriers in drug development and support innovation. It also mentions the 'IMI Call-Website' and provides information about the '2. Ausschreibung Innovative Medicines Initiative (IMI): Themen vorab veröffentlicht'.

**IPR: Vergleich
IMI-7.RP,
„Spielräume“**



FORSCHUNG WIRKT.

»» www.ffg.at



FFG



Urheberrechtshinweis / Haftungsausschluss

Sämtliche Texte, Grafiken und Bilder unterliegen dem Urheberrecht. Eine auch nur auszugsweise Verwendung ist nur mit ausdrücklicher Genehmigung der Österr. Forschungsförderungsgesellschaft mbH zulässig. Es kann keine Gewähr für Richtigkeit, Vollständigkeit und Aktualität der Angaben übernommen werden. Jede Haftung für Schäden, die durch Nutzung oder Nichtnutzung der dargestellten Informationen oder durch fehlerhafte oder unvollständige Informationen verursacht wurden, ist ausgeschlossen.